

Cavadis closes Series A financing round

Utrecht, the Netherlands – May 26, 2009 – Cavadis announced today the successful completion of its Series A financing round. Cavadis, a biomedical company active in the field of atherosclerosis, develops and exploits a portfolio of cardiovascular biomarkers. The company will use the proceeds of the placement to develop a “plaque” diagnostic kit to identify patients at risk of developing heart attacks and strokes, and to accelerate its discovery program to identify a series of predictive biomarkers in blood or circulating cells.

Cavadis welcomes the equity investment of the dedicated life sciences investor Thuja Capital who led the financing round, while the company is very pleased with the ongoing commitment of its existing investors, ErasmusMC Biomedical Fund, UMC Utrecht Holding BV and Universiteit Utrecht Holding BV.

“We are pleased to have attracted Thuja Capital to strengthen our shareholders’ base. Cavadis will capitalize on their expertise and experience in bringing young biotech companies to the next stage”, said Heico Breek, CEO of Cavadis.

In the past year Cavadis has made substantial progress on the discovery side, generating a large portfolio of cardiovascular biomarkers and a series of atherosclerotic plaque derived protein signatures with a predictive power far stronger than any of the traditional cardiovascular risk factors. With this new funding the company will be able to develop a multi-marker panel based diagnostic test to identify patients at high risk of secondary cardiovascular events, hereby addressing the asymptomatic nature of atherosclerotic disease. Cavadis’ cardiovascular biomarker portfolio also attracted the interest of big pharma and diagnostic companies and several collaborations have already been initiated.

“We are excited by Cavadis’ innovative and clever scientific approach to identify new biomarkers and the impressive achievements that they have accomplished to date. We are determined to help Cavadis to become successful as a key player in the field of cardiovascular diagnostics and biomarkers” said Michel Briejer, Investment Director at Thuja Capital, who will join the Supervisory Board of Cavadis.

For further information please contact

Heico Breek
Chief Executive Officer
+ 31 6 51 94 75 22
heico.breek@cavadis.com

About Cavadis

Cavadis BV is a Dutch biomedical company active in the field of atherosclerosis, developing and exploiting a portfolio of cardiovascular biomarkers predictive of future cardiovascular adverse events. The company’s biomarker discovery platform is based on a unique ongoing biobank study (Athero-Express) linking atherosclerotic plaque material of >2000 patients to long term follow-up clinical data. To date Cavadis has generated a robust portfolio of >150 cardiovascular biomarkers. Recently, the company discovered its first “plaque” protein signature highly predictive of future cardiovascular adverse events. The predictive power of this multi-marker panel is far stronger than any of the traditional risk factors such as cholesterol, blood pressure, overweight, smoking and hereditary factors. Based on this signature the company is developing a plaque diagnostic kit to identify patients at risk of developing secondary heart attacks and strokes. For more information please visit our website at: www.cavadis.com

About Thuja Capital

The Thuja Capital Healthcare Seed Fund (TCHSF) is a venture capital fund structured to invest in life sciences innovations with a focus on therapeutics, diagnostics and medical devices. The prime focus of TCHSF is on privately held early-stage life sciences companies located in the Netherlands.

The Thuja Capital Healthcare Seed Fund and the Thuja Capital Healthcare Fund are managed by Thuja Capital. In addition, Thuja Capital is the exclusive manager of AlInvest Partners' portfolio of early stage life sciences companies. Thuja Capital's team has a long-standing track record in successful life science investments. Apart from equity investments, Thuja Capital aims to actively help their portfolio companies to strengthen and grow their businesses. More information can be found on the web: www.thujacapital.com

About Erasmus MC Biomedical Fund

The Erasmus MC Biomedical Fund is an independent venture capital fund focusing on early stage companies and (university) spin-outs in the biotechnology and biomedical field with a presence in the Rotterdam region. The fund targets companies that are developing commercially promising products and technologies in life sciences, including pharmaceuticals, biotechnology, information technology and other high technology opportunities that offer venture capital returns. Please visit www.erasmuscfund.nl

About Utrecht Holdings

Utrecht Holdings is a collaborative union of Universiteit Utrecht Holding BV and UMC Utrecht Holding BV. It controls the patent portfolios of Utrecht University and the University Medical Centre Utrecht and is responsible for the successful exploitation of these portfolios. In addition, Utrecht Holdings is involved in spinning out companies from these institutes. Please visit www.utrechtholdings.nl for more information.